| 49.85 0.48 (0.97%) | 11-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 59.72 | 1-year : | 69.75 |
| Resists | First : | 51.13 | Second : | 59.72 |
| Pivot price | 39.85  |
|||
| Supports | First : | 40.61 | Second : | 34.11 |
| MAs | MA(5) : | 47.11 |
MA(20) : | 38.97 |
| MA(100) : | 43.42 |
MA(250) : | 37.56 |
|
| MACD | MACD : | 1.6 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 91 |
D(3) : | 89.8 |
| RSI | RSI(14): 74.6 |
|||
| 52-week | High : | 52.9 | Low : | 22.92 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ AXGN ] has closed below upper band by 7.7%. Bollinger Bands are 178.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 49.93 - 50.22 | 50.22 - 50.48 |
| Low: | 47.43 - 47.74 | 47.74 - 48.02 |
| Close: | 48.92 - 49.42 | 49.42 - 49.88 |
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
Fri, 30 Oct 2026
Axogen: Taking The Friction Out Of Nerve Repair (NASDAQ:AXGN) - Seeking Alpha
Thu, 29 Oct 2026
Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Thu, 29 Oct 2026
Axogen Inc (AXGN) (Q3 2026) Earnings Call Highlights: Revenue Jumps 26% as Breast Market Surges ... - Yahoo Finance
Wed, 28 Oct 2026
AxoGen Q3 Earnings Call Highlights - TradingView
Wed, 28 Oct 2026
AxoGen, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Wed, 28 Oct 2026
Axogen (AXGN) Q3 2026 Earnings Call Transcript - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 59 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 97.6 (%) |
| Shares Short | 4,700 (K) |
| Shares Short P.Month | 3,810 (K) |
| EPS | -0.68 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.78 |
| Profit Margin | -13.4 % |
| Operating Margin | -3.1 % |
| Return on Assets (ttm) | -3.2 % |
| Return on Equity (ttm) | -18.3 % |
| Qtrly Rev. Growth | 23.1 % |
| Gross Profit (p.s.) | 3.19 |
| Sales Per Share | 4.28 |
| EBITDA (p.s.) | -0.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 15 (M) |
| Levered Free Cash Flow | 18 (M) |
| PE Ratio | -74.41 |
| PEG Ratio | 99 |
| Price to Book value | 10.42 |
| Price to Sales | 11.64 |
| Price to Cash Flow | 194.33 |
| Dividend | 1 |
| Forward Dividend | 0 |
| Dividend Yield | 2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|